title: End of the line for sirolimus in liver transplant recipients with hepatitis C virus?
authors.forename: Paolo
authors.initials: P
authors.lastname: De Simone
authors.forename: Faouzi
authors.initials: F
authors.lastname: Saliba
authors.forename: Lutz
authors.initials: L
authors.lastname: Fischer
mesh_terms: D005260:Female; D006084:Graft Rejection / Q000401:mortality* / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects*; D006526:Hepatitis C / Q000401:mortality*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality*; D008297:Male; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus